Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Neuro-Oncology Practice · 05.02.2025 · 12 (1) · 34-44
DOI: 10.1093/nop/npae082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 24.09.2024. Verfasst von Vincent Fougner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danish Comprehensive Cancer Center - Brain Tumor Center.
Abstract (Originalsprache)
Background
In 2016, genomic profiling was implemented for patients with grade 4 primary brain tumors at Rigshospitalet, Denmark. The aim of this study was to discover actionable alterations and to match these with targeted therapies.
Methods
Between January 2016 and December 2023, 483 brain tumor patients were profiled. We retrieved clinical data and molecular data. Whole exome, whole genome, or panel sequencing, along with SNP array analyses, and RNA-seq were performed on resected primary tumor tissue. Alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT) following the European Association of Neuro-Oncology (EANO) guideline on rational molecular testing.
Results
A total of 200 (41.4%) patients’ tumors harbored an alteration of interest according to the EANO guideline. Twenty (4.1%) patients had an ESCAT high-tier alteration (tier I or II), while 155 patients (32.1%) had an alteration corresponding to ESCAT IIIA. Thirty-five patients (7.2%) had an actionable alteration, and 15 (3.1%) received targeted therapy. The treated targets were BRAFV600E mutations, FGFR alterations, NTRK fusions, PDGFRA fusions, PTPRZ1-MET fusions, and TMB-high. The overall response rate was 20%, with a median duration of response of 12 months, and 47% achieved stable disease as the best response.
Conclusions
Genomic profiling uncovers alterations of interest in a substantial number of patients, but only a minority are considered by the Danish National Molecular Tumor Board to have actionable alterations, and even fewer receive targeted therapy. Nevertheless, factors, such as promising targets and the increasing availability of trials, may contribute to a future increase in the number of patients benefiting from targeted therapies based on genomic profiling.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Danish Comprehensive Cancer Center - Brain Tumor Center (DCCC-BTC), Copenhagen, Denmark.
- Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Phase 1 Unit, Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Vincent Fougner, Hans Skovgaard Poulsen, Linea Cecilie Melchior
Förderung
- Danish Comprehensive Cancer Center - Brain Tumor Center
Zitieren
APA
Fougner, V., Urup, T., Poulsen, H. S., Grunnet, K., Westmose, C. Y., Melchior, L. C., Larsen, K. B., Højgaard, M., Spanggaard, I., Belcaid, L., Rohrberg, K. S., Lassen, U., Hasselbalch, B., & Nørøxe, D. S. (2025). Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023. Neuro-Oncology Practice, 12(1), 34-44. https://doi.org/10.1093/nop/npae082
Vancouver
Fougner V, Urup T, Poulsen HS, Grunnet K, Westmose CY, Melchior LC, et al. Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023. Neuro-Oncology Practice. 2025;12(1):34-44. doi:10.1093/nop/npae082
BibTeX
@article{Fougner2025,
author = {Fougner, Vincent and Urup, Thomas and Poulsen, Hans Skovgaard and Grunnet, Kirsten and Westmose, Christina Yde and Melchior, Linea Cecilie and Larsen, Karen Bonde and Højgaard, Martin and Spanggaard, Iben and Belcaid, Laila and Rohrberg, Kristoffer Staal and Lassen, Ulrik and Hasselbalch, Benedikte and Nørøxe, Dorte Schou},
title = {Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023},
journal = {Neuro-Oncology Practice},
year = {2025},
volume = {12},
number = {1},
pages = {34--44},
doi = {10.1093/nop/npae082}
}
EUVIMED